BIOMAT Database Logo BIOMAT Database Logo

[The pros and cons of intravitreal drug injection]. 2011

Fumi Gomi

UI MeSH Term Description Entries
D009877 Endophthalmitis Suppurative inflammation of the tissues of the internal structures of the eye frequently associated with an infection. Ophthalmia,Infectious Endophthalmitis,Endophthalmitides,Endophthalmitides, Infectious,Endophthalmitis, Infectious,Infectious Endophthalmitides,Ophthalmias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068258 Bevacizumab An anti-VEGF humanized murine monoclonal antibody. It inhibits VEGF RECEPTORS and helps to prevent PATHOLOGIC ANGIOGENESIS. Avastin,Bevacizumab-awwb,Mvasi,Bevacizumab awwb
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D058449 Intravitreal Injections The administration of substances into the VITREOUS BODY of the eye with a hypodermic syringe. Injection, Intravitreal,Injections, Intravitreal,Intravitreal Injection
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies
D020533 Angiogenesis Inhibitors Agents and endogenous substances that antagonize or inhibit the development of new blood vessels. Angiogenesis Factor Inhibitor,Angiogenesis Inhibitor,Angiogenetic Antagonist,Angiogenetic Inhibitor,Angiogenic Antagonist,Angiogenic Antagonists,Angiogenic Inhibitor,Angiostatic Agent,Angiostatic Agents,Anti-Angiogenetic Agent,Anti-Angiogenic Drug,Anti-Angiogenic Drugs,Antiangiogenic Agent,Neovascularization Inhibitor,Neovascularization Inhibitors,Angiogenesis Factor Inhibitors,Angiogenetic Antagonists,Angiogenetic Inhibitors,Angiogenic Inhibitors,Antagonists, Angiogenic,Anti-Angiogenesis Effect,Anti-Angiogenesis Effects,Anti-Angiogenetic Agents,Antiangiogenesis Effect,Antiangiogenesis Effects,Antiangiogenic Agents,Inhibitors, Angiogenesis,Inhibitors, Angiogenetic,Inhibitors, Angiogenic,Inhibitors, Neovascularization,Agent, Angiostatic,Agent, Anti-Angiogenetic,Agent, Antiangiogenic,Agents, Angiostatic,Agents, Anti-Angiogenetic,Agents, Antiangiogenic,Antagonist, Angiogenetic,Antagonist, Angiogenic,Antagonists, Angiogenetic,Anti Angiogenesis Effect,Anti Angiogenesis Effects,Anti Angiogenetic Agent,Anti Angiogenetic Agents,Anti Angiogenic Drug,Anti Angiogenic Drugs,Drug, Anti-Angiogenic,Drugs, Anti-Angiogenic,Effect, Anti-Angiogenesis,Effect, Antiangiogenesis,Effects, Anti-Angiogenesis,Effects, Antiangiogenesis,Factor Inhibitor, Angiogenesis,Factor Inhibitors, Angiogenesis,Inhibitor, Angiogenesis,Inhibitor, Angiogenesis Factor,Inhibitor, Angiogenetic,Inhibitor, Angiogenic,Inhibitor, Neovascularization,Inhibitors, Angiogenesis Factor

Related Publications

Fumi Gomi
Intravitreal administration of bevacizumab: pros and cons.
April 2015, Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences,
Fumi Gomi
The pros and cons of drug 'trafficking'.
November 1995, Nature medicine,
Fumi Gomi
Preemployment drug screening: pros and cons.
November 1973, JAMA,
Fumi Gomi
[Surveillance of drug use--pros and cons].
August 2009, Deutsche medizinische Wochenschrift (1946),
Fumi Gomi
[Fixed drug combinations--the pros and the cons].
April 2009, Medizinische Monatsschrift fur Pharmazeuten,
Fumi Gomi
Chirality and drug targeting: pros and cons.
January 1995, Journal of drug targeting,
Fumi Gomi
Drug company-sponsored symposia: pros and cons.
October 1987, The American journal of medicine,
Fumi Gomi
The Pros and Cons of the PROs.
February 2018, Aesthetic surgery journal,
Fumi Gomi
[The pros and cons of drug therapy for hypertension].
February 1972, Die Medizinische Welt,
Fumi Gomi
Pros and cons of prescription drug benefit changes.
January 2003, Physician executive,
Copied contents to your clipboard!